
    
      This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be
      randomly assigned to one of the three treatment groups (CJ-12420 50 mg or 100 mg or placebo).

      All subjects will be asked to take two tablets at the same time each day throughout the
      study, and also all subjects will be asked to record daily symptom in a subject diary on a
      daily basis.
    
  